Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients

International Journal of Neuropsychopharmacology

Volumn 3, Issue 1, 2000, Pages 61-65

  Lovlie, Roger ^a   Daly, Ann K ^b   Blennerhassett, Richard ^b   Ferrier, Nicol ^b   Steen, Vidar M ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Dopamine; DRD3; Schizophrenia; Tardive dyskinesia

Indexed keywords

DNA; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0034092396     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145700001796     Document Type: Article

References (22)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: American Psychiatric Association.
2. Andreassen OA, MacEwan T, Gulbrandsen A-K, McCreadie RG, Steen VM (1997). Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 131, 174-179.
3. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR (1997). Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. British Journal of Psychiatry 170, 23-26.
4. Aschauer HN, Scharfetter J, Hornik K, Fuchs K, Gerhard E, Gebhardt C, Lenzinger E, Meszaros K, Sieghart W, Kasper S (1998). Tardive Dyskinesia is not associated to dopamine D3-and dopamine-beta-hydroxylase-genes in Austrian schizophrenics. American Journal of Medical Genetics 81, 499.
5. Basile V, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin S, Macciardi F, Kennedy JL (1999). Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21, 17-27.
6. Kane JM (1995). Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (Eds), Psychopharmacology: The Fourth Generation of Progress (pp. 1485-1495). New York: Raven Press.
7. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jönsson E, Sedvall G, Schwartz JC (1992). Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatric Genetics 2, 249-256.
8. Liddle PF, Barnes TRE, Speller JC, Kibel D (1993). Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. British Journal of Psychiatry 163, 776-780.
9. Lundstrom K, Turpin MP (1996). Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with Semliki forest virus system. Biochemical and Biophysical Research Communications 225, 1068-1072.
10. McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon MS (1996). Abnormal movements in never-medicated Indian patients with schizophrenia. British Journal of Psychiatry 168, 221-226.
11. Morgenstern H, Glazer WM (1993). Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Archives of General Psychiatry 50, 723-733.
12. Müller DJ, Ahle G, Alfter D, Krauss H, Knapp M, Marwinski K, Schulze TG, Weber T, Nöthen M, Maier W, Held T, Rietschel M (1998) Familial occurrence of tardive dyskinesia. American Journal of Medical Genetics 81, 527.
13. Owens DG, Johnstone EC, Frith CD (1982). Spontaneous involuntary disorders of movement : their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Archives of General Psychiatry 39, 452-461.
14. Rietschel M, Nöthen MM, Albus M, Krauss H, Fimmers R, Held T, Macciardi F, Maier W, Propping P (1997). Frequency of the dopamine D3 receptor variant in a sample of schizophrenic patients with a positive family history and in a sample with tardive dyskinesia. American Journal of Medical Genetics 74, 628.
15. Rohrmeier T, Albus M, Wildenauer D, Schwab S, Putzhammer A, Schoeler A, Sartor H, Eichammer P (1998). Dopamine D3 receptor gene variants and susceptibility to early dyskinesia. American Journal of Medical Genetics 81, 498.
16. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B (1999). Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Molecular Psychiatry 4, 247-253.
17. Steen VM, Lovlie R, MacEwan T, McCreadie RG (1997). Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular Psychiatry 2, 139-145.
18. US Department of Health, Education & Welfare (1976). Abnormal involuntary movements scale. In: Guy W (Ed.), ECDEU Assessment Manual. Rockville, MD, USA: US Department of Health, Education & Welfare.
19. Waddington JL, Youssef HA (1996). Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine 26, 681-688.
20. Waddington JL, Youssef HA, Kinsella A (1990). Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine 20, 835-842.
21. Yassa R, Ananth J (1981). Familial tardive dyskinesia. American Journal of Psychiatry 138, 1618-1619.
22. Youssef H, Lyster G, Youssef F (1989). Familial psychosis and vulnerability to tardive dyskinesia. International Clinical Psychopharmacology 4, 323-328.